The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma

Hatem A Sarhan, Omar H El-Garhy, Mohamed A Ali, Nouran A Youssef, Hatem A Sarhan, Omar H El-Garhy, Mohamed A Ali, Nouran A Youssef

Abstract

Objective: Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma.

Methods: A double-blind randomized controlled study was conducted in Chest and Emergency Departments. Thirty patients of acute attack of bronchial asthma were randomized into three groups: MgSO4 nebulization (group A), salbutamol nebulization (group B), and their combination (group C). All patients were monitored before and after nebulization (each 20 minutes) for peak expiratory flow rate (PEFR), respiratory rate (RR), heart rate (HR), blood pressure, pulsus paradoxus, oxygen saturation, clinical examination, and Fischl index.

Results: A highly significant improvement in PEFR, PEFR percentage, and Fischl index and significant decrease in RR and HR was observed in all groups. A similar improvement in PEFR was observed in group A and group B (P=0.389). The difference in peak expiratory flow (PEF) improvement was insignificant between group B and group C (P=0.101), while there was a significant difference between group A and group C (P=0.014) in favor of group C.

Conclusion: Nebulized MgSO4 alone or combined with salbutamol has a clinically significant bronchodilator effect in acute asthma and leads to clinical improvement, increase in PEFR, reduction in HR, and reduction in RR. The response to nebulized MgSO4 alone (PEFR improvement 54±35.6 L/min, P=0.001) is comparable (P=0.389) to that of nebulized salbutamol (PEFR improvement 67.0±41.9 L/min, P=0.001) and is significantly less than (P=0.014) that of nebulized combination (PEFR improvement 92.0±26.9 L/min, P=0.000).

Keywords: Fischl index; acute asthma; nebulized magnesium sulfate; peak expiratory flow rate; salbutamol.

References

    1. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. 2015. [Accessed on August 3, 2015]. Available from: .
    1. Morell F, Genover T, Reyes L, Benaqueb E, Rogera L, Ferrera J. Monitoring of asthma outpatients after adapting treatment to meet international guidelines. Archivos de Bronconeumología (English Edition) 2007;43(1):29–35.
    1. Refaat S, Aref H. Acute asthma in emergency department, prevalence of respiratory and non-respiratory symptoms. Egypt J Chest Dis Tuberc. 2014;63(4):776–771.
    1. Annesi-Maesano I. Epidemiology of asthma in the world and in France. Rev Prat. 2011;61(3):329–335.
    1. Shan Z, Rong Y, Yang W, et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med. 2013;107(3):321–330.
    1. Blitz M, Blitz S, Hughes R, et al. Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005;128(1):337–344.
    1. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol. 2000;106(6):1033–1042.
    1. Abdelnabi EA, Kamel MM, Ali AE. Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma. Egypt J Chest Dis Tuberc. 2012;61(3):29–34.
    1. Bateman E, Hurd S, Barnes P, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178.
    1. Chien JW, Ciufo R, Novak R, et al. Uncontrolled oxygen administration and respiratory failure in acute asthma. Chest. 2000;117(3):728–733.
    1. Agarwal R, Gupta D. No role for inhaled magnesium sulfate in the treatment of acute asthma? Pulm Pharmacol Ther. 2007;20(5):494.
    1. Emond S. Addition of intravenous aminophylline to β2-agonist in adults with acute asthma. Ann Emerg Med. 2002;40(3):350–352.
    1. Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. Am Rev Respir Dis. 1985;132(2):283–286.
    1. Talukdar T, Singhal P, Jain A, Kumar R, Gaur SN. Inhaled magnesium sulfate in the treatment of severe asthma. Indian J Allergy Asthma Immunol. 2005;19(1):29–35.
    1. Rowe BH, Camargo CA, Multicenter Airway Research Collaboration The use of magnesium sulfate in acute asthma: rapid uptake of evidence in North American emergency departments. J Allergy Clin Immunol. 2006;117(1):53–58.
    1. Goodacre S, Cohen J, Bradburn M, Gray A, Benger J, Coats T, 3Mg Research Team Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(4):293–300.
    1. Okayama H, Aikawa T, Okayama M, Sasaki H, Mue S, Takishima T. Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA. 1987;257(8):1076–1078.
    1. Skobeloff EM, Spivey WH, McNamara RM, Greenspon L. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA. 1989;262(9):1210–1213.
    1. Noppen M, Vanmaele L, Impens N, Schandevyl W. Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma. Chest. 1990;97(2):373–376.
    1. Okayama H, Okayama M, Aikawa T, Sasaki M, Takishima T. Treatment of status asthmaticus with intravenous magnesium sulfate. J Asthma. 1991;28(1):11–17.
    1. Singh AK, Gaur S, Kumar R. A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iran J Allergy Asthma Immunol. 2008;7(4):221–229.
    1. Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014;5:Cd010909.
    1. Nannini LJ, Jr, Pendino JC, Corna RA, Mannarino S, Quispe R. Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. Am J Med. 2000;108(3):193–197.
    1. Bessmertny O, DiGregorio RV, Cohen H, et al. A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Ann Emerg Med. 2002;39(6):585–591.
    1. Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet. 2003;361(9375):2114–2117.
    1. Kokturk N, Turktas H, Kara P, Mullaoglu S, Yilmaz F, Karamercan A. A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks. Pulm Pharmacol Ther. 2005;18(6):416–421.
    1. Aggarwal P, Sharad S, Handa R, Dwiwedi SN, Irshad M. Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. Emerg Med J. 2006;23(5):358–362.
    1. Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther. 2010;23(5):432–437.
    1. Britton J, Pavord I, Richards K, et al. Dietary magnesium, lung function, wheezing, and airway hyper-reactivity in a random adult population sample. Lancet. 1994;344(8919):357–362.
    1. Fischl MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med. 1981;305(14):783–789.
    1. Mangat H, D’Souza G, Jacob M. Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial. Eur Respir J. 1998;12(2):341–344.
    1. Dadhich P, Vats M, Lokendra D, et al. Magnesium sulphate nebulization in acute severe asthma. Chest. 2003;124(4_MeetingAbstracts):107S.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren